Danaher/Abcam deal set to close next month; Cereno's loan; March Biosciences to advance its CAR-T into PhII
Danaher’s proposed acquisition of Abcam is expected to close Dec. 6: The companies announced the closing date on Friday. Danaher is paying $24 a share in cash. Jonathan Milner, Abcam’s founder and largest shareholder, had campaigned against the deal until earlier this month.
Cereno Scientific’s loan: The Swedish biopharma developing cardiovascular treatments said Friday it received a loan for SEK 90 million, about $8.5 million. Formue Nord Fokus issued the loan, which is divided into two tranches, at a set-up fee of 5%. “We have secured optimal conditions to be able to maintain a strong position in discussions and potential negotiations with partners over an extended period,” Cereno CEO Sten Sörensen said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.